These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 12555216)

  • 1. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of fetal hemoglobin response to hydroxyurea.
    Steinberg MH
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
    Rodgers GP
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
    Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
    Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
    Kattamis A; Lagona E; Orfanou I; Psichou F; Ladis V; Kanavakis E; Metaxotou-Mavrommati A; Kattamis C
    Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fetal hemoglobin in sickle cell anemia: Bayesian modeling of genetic associations.
    Sebastiani P; Wang L; Nolan VG; Melista E; Ma Q; Baldwin CT; Steinberg MH
    Am J Hematol; 2008 Mar; 83(3):189-95. PubMed ID: 17918249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P; Barretto de Mello A; Figueiredo MS
    Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
    Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
    Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
    Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
    Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hydroxyurea, erythrocyte volumes and hemoglobin F].
    Bargetzi MJ; Schönenberger A; Tichelli A; Passweg J; Rabaglio M; Singer D; Sissolak G; Gratwohl A; Speck B
    Schweiz Med Wochenschr; 1995 Mar; 125(9):433-5. PubMed ID: 7534433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominant influence of gamma-globin promoter polymorphisms on fetal haemoglobin expression in sickle cell disease.
    Ofori-Acquah SF; Lalloz MR; Serjeant G; Layton DM
    Cell Mol Biol (Noisy-le-grand); 2004 Feb; 50(1):35-42. PubMed ID: 15040425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localisation of cis regulatory elements at the beta-globin locus: analysis of hybrid haplotype chromosomes.
    Ofori-Acquah SF; Lalloz MR; Layton DM
    Biochem Biophys Res Commun; 1999 Jan; 254(1):181-7. PubMed ID: 9920754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
    Koc A; Gumruk F; Gurgey A
    Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
    Rodgers GP; Dover GJ; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1990 Apr; 322(15):1037-45. PubMed ID: 1690857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.